Cosmetic matrikine peptide blend (topical)

Matrixyl 3000

Matrixyl 3000 is Sederma's blend of two palmitoylated matrikine peptides; the app lists a half-life of 4 hours, but none of the sources read reports one for it.1

Moderate evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Matrixyl 3000 after one dose: 50% at ~4 h, 25% at 8 h, 12.5% at 12 h.

Drawn from the half-life in the app's model, ~4 h. The model's figures

Matrixyl 3000 is a cosmetic ingredient sold by Sederma, a member of Croda International Plc.1 Sederma's data sheet defines it as an "Association of 2 palmitoylated matrikines" and names them Pal-Gly-His-Lys and Pal-Gly-Gln-Pro-Arg.1 The listed ingredient names are palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, with glycerin, water, butylene glycol, carbomer and polysorbate 20 as the carrier.1 The sheet gives "Anti-wrinkle" as its function and "Anti-wrinkle products" as its application.1 Palmitoyl tripeptide-1 was formerly named palmitoyl oligopeptide, which the older 2007 sheet still uses in its ingredient list, and that sheet gives palmitoyl tetrapeptide-3 as the former name of palmitoyl tetrapeptide-7.1,2 A 2021 review in Pharmaceuticals states that the name palmitoyl oligopeptide was removed in 2013 because it had designated two distinct molecules, which were renamed palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl hexapeptide-12 (Pal-KTTKS).3 The app files Matrixyl 3000 as a cosmetic matrikine peptide, grades the evidence as moderate, and lists a topical route and a typical concentration of 3 to 8%. The evidence summarised below consists of a manufacturer's technical sheets, one 12-week trial of an eye cream that contains the same two peptides, one preliminary peptide-blend methods study from Sederma, one permeation study and a cosmetic-ingredient safety review. The app's category field reads "tanning", and none of the sources read describes a tanning use.

Sederma's sheet describes matrikines as "messenger peptides capable of regulating cell activities by interacting with their specific receptors".1 The sheet says they "activate certain genes involved in the process of extracellular matrix renewal and cell proliferation".1 It also states that "Matrixyl®3000 supports the activation of the cutaneous repair process".1 These are the manufacturer's statements, and the sheet's non-warranty states that "Suggestions for uses or applications are only opinions". The 2021 review states that palmitoyl tetrapeptide-7 "decreases IL-6 secretion, reduces inflammation after UVB exposure and stimulates laminin IV and V as well as collagen VII production", and it describes the peptide as a fragment of immunoglobulin G.3 Yang and colleagues, in Skin Research and Technology in 2024, write that palmitoyl tripeptide-1 "can stimulate the synthesis of ECM components such as types I and III collagen, elastin" and fibronectin, and that palmitoyl tetrapeptide-7 "could increase skin elasticity, firmness, and smoothness".4 In cultured human fibroblasts, a complex of the two peptides with yeast/rice fermentation filtrate and N-acetylneuraminic acid raised Col I A1, Col III A1 and Col IV A1 mRNA by 1.8, 2.5 and 2.8 times and elastin mRNA to about fivefold the untreated control.4 That is a cell result on a multi-component complex, and it does not show the effect of either peptide alone or of Matrixyl 3000 itself.4

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~4 h
Bioavailability
95%
Typical dose
3–8%
Route
Topical
Time to peak
~0.5 h

The app lists a half-life of about 4 hours, a bioavailability of 95% and a time to peak of 0.5 hours, and its own note says systemic pharmacokinetic tracking does not apply because the ingredient has negligible systemic absorption. None of the sources read gives a blood concentration, a half-life, a bioavailability or a time to peak for Matrixyl 3000 or either peptide. What a source does report is where the peptides sit in the skin: Trzaska and colleagues, University of Nottingham, International Journal of Pharmaceutics, 2026, applied serums containing Matrixyl 3000 to three healthy female volunteers for 0.5, 2 and 5 hours.5 They report that Pal-GHK and Pal-GQPR were detected "throughout every layer of the stratum corneum, demonstrating decreasing ion intensities with depth and no significant changes relative to exposure time".5 Their reading is that the intensities "dropped immediately", "suggesting that they were only present on the outer surfaces of the cells and not within them (intercellular)".5

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-life~4 hNone of the sources read reports a half-life for the blend or either peptide
Bioavailability95%No systemic measurement reported; both peptides were detected in every stratum corneum layer sampled, with falling intensity at depth in three volunteers5
Time to peak~0.5 hNo peak time reported; the shortest sampling time in the permeation study was 0.5 h, and the authors saw no significant change with exposure time5
RouteTopicalApplied to skin as creams or serums in the studies read4,5
4

Human studies

The studies below include creams with the blend, an eye cream with the two peptides, and a methods study of a peptide blend, and are separated by what was actually tested.

Table 4.1Human studies4 rows
Study and yearDesignPeopleDose and lengthMain result
Yang and colleagues, Skin Research and Technology 20244Treated side against control side of the periorbital area; indexed as a randomized controlled trial, while the authors also write that there was no control or placebo group; product contained both peptides plus yeast/rice fermentation filtrate and N-acetylneuraminic acid; authors from the product maker37 healthy women, average age 44.6 ± 6.2 yearsEye cream twice daily for 12 weeks; peptide concentration not stated in the text readAuthors report hydration +28.12%, elasticity +18.81% and collagen production +54.99% at 12 weeks; dermatologists observed no adverse reactions
Mondon and colleagues, Journal of Cosmetic Dermatology 20156Methods study with a placebo comparison; blend of palmitoyl oligopeptide and palmitoyl tetrapeptide-7; five of the authors at SedermaNumber of people and dose not stated in the text readNot stated in the text readEchography: the blend "reduced subepidermal low-echogenic band thickness and improved its density"; confocal microscopy: ECM structure improved against placebo
Sederma data sheet, 2015 (manufacturer, not peer reviewed)1Half-face cream against placebo, twice daily23 women aged 42 to 67 yearsCream with 3% Matrixyl 3000; 2 monthsAgainst baseline, deep-wrinkle surface -39.4 (product side) and 4.3 ns (placebo side), main wrinkle density -32.9 and -9.9 ns, elasticity +5.5 and 4.1 ns
Sederma data sheet, 2007 (manufacturer, not peer reviewed)2Half-face cream against placebo, twice daily39 men aged 54.5 ± 6 yearsCream with 4% Matrixyl 3000; 56 daysAgainst baseline, deep-wrinkle surface -29.4 and +5.1 ns (placebo side), main furrows density -30.4 and -19.7 ns, roughness -8.4 and -2.2 ns

Deeper analysis: the Yang eye cream trial

Yang and colleagues, with authors from Mageline Biology Tech in Wuhan, Shanghai Skinshield Clinical Testing, the Air Force Medical Center in Beijing and Union Hospital in Wuhan, tested a commercial eye cream whose actives were yeast/rice fermentation filtrate, N-acetylneuraminic acid, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.4 The paper does not name Matrixyl 3000 or state the source of its two peptides, so its result is for a multi-component formulation and does not isolate the Sederma blend. The 37 women were healthy, and the twice-daily application ran for 12 weeks on one side of the periorbital area, with the other side as the control.4 Hydration was higher on the treated side by 5.8% at 2 weeks and by 14.1%, 20.9% and 28.1% at 4, 8 and 12 weeks.4 Collagen density from ultrasound rose by 17.5%, 20.0% and 55.0% at 4, 8 and 12 weeks.4 For elasticity, the summary of results gives 18.81% at 12 weeks, while the results text gives R2, R5 and R7 increases of 14.1%, 20.9% and 28.1% at 12 weeks, the same three figures it gives for hydration at 4, 8 and 12 weeks.4 The dermatologists' scores reached significance "after 8 weeks of using the eye cream compared to the control side", so the 4-week scores for some indicators were not significant.4 Safety findings were that dermatologists observed no adverse reactions such as skin papules, erythema, scabbing or desquamation, and the authors report that "All participants reported experiencing mildness and comfort".4 The authors list their own limits: "The sample size of participants in our clinical trial is relatively small", and "the current study did not include a control or placebo group, which could lead to bias in the interpretation of the results".4 The same paper's text also calls the trial randomized, double-blind and controlled, so its own description of the control arm is not consistent.4 The paper states "No conflict of interest was reported by the authors", and the text read contains no funding statement.4

Deeper analysis: the Mondon peptide-blend study

Mondon and colleagues, Sederma with the University of Rouen and Sorbonne laboratories, report in the Journal of Cosmetic Dermatology in 2015 a study whose stated purpose was "to establish a new methodology for evaluating elements of dermal extracellular matrix (ECM)".6 Its peptide evaluation used "a blend of palmitoyl oligopeptide and palmitoyl tetrapeptide-7"; the Sederma sheet gives palmitoyl oligopeptide as the former name of palmitoyl tripeptide-1, but the 2021 review says the name had designated two distinct molecules, and the Mondon record does not name Matrixyl 3000.6,1,3 The authors report that echography showed the blend "reduced subepidermal low-echogenic band thickness and improved its density", and that confocal microscopy "indicated that the peptides improved the ECM structure vs. placebo".6 They call it a "preliminary" study that "raised some technical difficulties that were overcome", and write that "Further studies will be conducted".6 The text read gives no participant number, concentration, duration, funding statement or conflict statement for the peptide part; five of the nine listed authors have a Sederma affiliation, and Sederma sells Matrixyl 3000.6,1

Deeper analysis: the Sederma in vivo data

The two data sheets give design lines for three in vivo studies, all by the manufacturer, with creams containing 3% or 4% Matrixyl 3000 applied to one half of the face against a placebo, and in the 28-woman study also to the forearm.1,2 In the 28-woman study the sheet reports thickness of the subepidermal low-echogenicity band at -5.5% against placebo and density at +7.8% against placebo on the inner arm after one month.1 In the 23-woman profilometry study, the product side changed against baseline by -39.4 for deep-wrinkle surface and -32.9 for main wrinkle density, and the placebo side by 4.3 and -9.9, both marked non significant.1 The placebo side also showed a significant change in main wrinkle average volume (-8.7 against -23.3 on the product side), and the sheet tests each side against its own baseline (T0) rather than product against placebo.1 In the 39-man study the product side changed by -29.4 for deep-wrinkle surface and -30.4 for main furrows density, while the placebo side changed by +5.1 and -19.7, both marked non significant.2 The sheets give no confidence intervals, no adverse-event data, no dropout numbers and no funding statement beyond the maker's own authorship, and they carry a non-warranty stating that "Suggestions for uses or applications are only opinions".1,2

Deeper analysis: the Trzaska permeation study

Trzaska and colleagues at the University of Nottingham School of Pharmacy studied "the in vivo permeation behaviour of these cosmetic actives through the stratum corneum of three healthy female volunteers".5 Matrixyl 3000 was one of three actives tested, applied in a serum for 0.5, 2 and 5 hours, with tape stripping of the skin followed by OrbiSIMS analysis.5 Both peptides were detected in every layer, with falling intensity at depth and "no significant changes relative to exposure time".5 The study measured location in the stratum corneum and not the effect on wrinkles, collagen or any systemic level, and the text read does not give the peptide concentration of the serum.5 Two authors are employees of No7 Beauty Company, The Boots Group, and the authors "declare that there are no competing interests that could have appeared to influence the work reported in this paper".5

5

Doses reported in studies and on labels

The app lists a typical concentration of 3 to 8%, while the Sederma data sheets give a recommended use level of 3% (2015) and 3 - 4% (2007).1,2 A DailyMed search for "palmitoyl tripeptide-1" on 16 November 2026 found six cosmetic product listings and none for Matrixyl 3000 itself, and no regulator label or monograph for it was among the sources read.

Table 5.1Doses reported in studies and on labels7 rows
SourceProduct and contextConcentrationSchedule and lengthReference
Sederma data sheet, 2015Recommended use level of the ingredient3%Not stated1
Sederma data sheet, 2007Recommended use level of the ingredient3 - 4%Not stated2
Sederma 2015 in vivo studiesCream applied to one half of the face against placebo; 23 and 28 women3%Twice daily, 2 months1
Sederma 2007 in vivo studyCream applied to one half of the face against placebo; 39 men4%Twice daily, 56 days2
Sederma 2015 in vitro senescence testSenescent fibroblasts in culture, a cell testMatrixyl 3000 eq 5%Not stated1
Yang and colleagues 2024Eye cream with both peptides, 37 womenPeptide concentration not stated in the text readTwice daily, 12 weeks4
Cosmetic Ingredient Review, 2018Typical use concentration of the peptide ingredients in cosmetic products, not of the Matrixyl 3000 blendBelow 10 ppmNot stated7

In the 12-week eye cream trial, dermatologists observed no adverse reactions such as skin papules, erythema, scabbing or desquamation in 37 women.4 The same paper states that a patch test of the product had results "indicating excellent safety" and that all samples of the active ingredients in fibroblast culture had "cell viability exceeding 90%".4 Participants with sensitive skin around the eyes "noted significant reductions in skin burning, itching, stinging, pruritus, and tightness".4 The Cosmetic Ingredient Review Expert Panel noted "the low use concentrations and negative safety test data reviewed" and concluded that these ingredients "are safe in cosmetics in the present practices of use and concentration described in this safety assessment".7 That assessment covers tripeptide-1, hexapeptide-12, their metal salts and fatty acyl derivatives, and palmitoyl tetrapeptide-7, at typical use concentrations below 10 ppm, and its scope is the individual ingredients and not the Matrixyl 3000 blend at the 3 to 8% the app lists.7 The Sederma sheets read report efficacy measures and do not report adverse events.1,2

7

Regulatory and anti-doping status

The 2026 World Anti-Doping Agency Prohibited List text read does not name palmitoyl tripeptide-1, palmitoyl tetrapeptide-7 or Matrixyl.8 Its S0 class covers "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use".8 The sources read do not say how that class applies to a cosmetic ingredient. The journal record of the Cosmetic Ingredient Review assessment gives a conclusion on safety in cosmetics and does not describe a regulatory approval.7

A PubMed query for "Matrixyl 3000 wrinkles" and a ClinicalTrials.gov query for "Matrixyl", both on 16 November 2026, returned no controlled trial of Matrixyl 3000 itself in a peer-reviewed journal; the placebo-controlled half-face studies are in the manufacturer's sheets. The efficacy figures for the blend come from the manufacturer's own sheets, which give no confidence intervals; the wrinkle tables compare each side with its own baseline, and the 28-woman echography results are given against placebo.1,2 The one trial of a product with both peptides among the sources read in full is small and used a multi-component cream, so the contribution of each peptide is not separated.4 No trial in people comparing the two peptides separately with the blend was identified in the searches. The permeation data come from three volunteers and measure stratum corneum location, not deeper skin levels or blood.5 The app's half-life, bioavailability and time to peak are not matched by a figure in any source read.

What is Matrixyl 3000?

Matrixyl 3000 is a Sederma cosmetic ingredient defined as an "Association of 2 palmitoylated matrikines".1 Its function is listed as "Anti-wrinkle".1

What is the half-life of Matrixyl 3000?

The app lists about 4 hours, and none of the sources read reports a half-life for Matrixyl 3000 or either peptide. The app's own note says the ingredient has negligible systemic absorption and the modeled curve does not reflect how it works.

What peptides are in Matrixyl 3000?

The two peptides are palmitoyl tripeptide-1 (Pal-Gly-His-Lys) and palmitoyl tetrapeptide-7 (Pal-Gly-Gln-Pro-Arg).1

Does Matrixyl 3000 get absorbed through the skin?

In three volunteers, both peptides were detected "throughout every layer of the stratum corneum", with falling intensity at depth.5 That study measured the stratum corneum only, and the app lists a bioavailability of 95% that no figure in the sources read supports.5

Has Matrixyl 3000 been tested in clinical trials?

Sederma's sheets report half-face studies in 23 women, 28 women and 39 men, and the sheets are manufacturer documents that are not peer reviewed.1,2 A 37-woman eye cream trial with both peptides reported hydration +28.12%, elasticity +18.81% and collagen production +54.99% at 12 weeks, and its authors list a small sample and no control or placebo group as limits.4

Is Matrixyl 3000 banned by WADA?

The 2026 WADA Prohibited List text read does not name palmitoyl tripeptide-1, palmitoyl tetrapeptide-7 or Matrixyl.8

What did the Cosmetic Ingredient Review conclude about the peptides in Matrixyl 3000?

The Expert Panel concluded that the ingredients it assessed, which include palmitoyl tetrapeptide-7, "are safe in cosmetics in the present practices of use and concentration described in this safety assessment".7 Its typical use concentrations were below 10 ppm.7

Is Matrixyl 3000 the same as Matrixyl?

Matrixyl 3000 contains Pal-GHK and Pal-GQPR, whereas the "Matrixyl (MTI)" in a 2022 ACS Omega wound-healing study is the pentapeptide Pal-KTTKS.1,9

Who makes Matrixyl 3000?

Sederma, a member of Croda International Plc, issues the data sheets for Matrixyl 3000.1

11

References

  1. Sederma. Matrixyl 3000: technical data sheet, v. 150429, 2015. Manufacturer document, not peer reviewed. Sederma data sheet (2015)
  2. Sederma. Matrixyl 3000: technical data sheet, claim substantiation dated May 2007. Manufacturer document, not peer reviewed. Sederma data sheet (2007)
  3. Resende DISP, et al. Usage of Synthetic Peptides in Cosmetics for Sensitive Skin. Pharmaceuticals (Basel) 2021. PMID 34451799
  4. Yang F, et al. Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream. Skin Res Technol 2024. PMID 38932444
  5. Trzaska AH, et al. Permeation behaviour of cosmetic actives into the human stratum corneum. Int J Pharm 2026. PMID 42790608
  6. Mondon P, et al. Evaluation of dermal extracellular matrix and epidermal-dermal junction modifications using matrix-assisted laser desorption/ionization mass spectrometric imaging, in vivo reflectance confocal microscopy, echography, and histology: effect of age and peptide applications. J Cosmet Dermatol 2015. PMID 25817264
  7. Johnson W, et al. Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics. Int J Toxicol 2018;37(3_suppl):90S-102S. CIR safety assessment
  8. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list
  9. Kachooeian M, et al. Matrixyl Patch vs Matrixyl Cream: A Comparative In Vivo Investigation of Matrixyl (MTI) Effect on Wound Healing. ACS Omega 2022. PMID 35874243